Evolving strategies in adjuvant treatment for stage IB cervical cancer after radical hysterectomy

E. Sartori, V. Zanagnolo, G. Tisi, S. Pecorelli, U. A. Bianchi

Research output: Contribution to journalArticle

Abstract

Objective: In stage IB cervical cancer patients after radical hysterectomy adjuvant radiation therapy is usually performed in node-positive subjects or patients with unfavourable prognostic factors on the surgical specimen. The aim of this paper is to retrospectively analyze the patterns of failure and survival in patients with stage IB cervical cancer after radical hysterectomy in relation to the main prognostic factors in view of the evolving strategies in adjuvant treatment. Methods: Site of recurrence and survival data were reviewed for 215 stage IB cervical carcinoma patients after radical surgery in a 10-year period. The incidence of positive nodes was 25.2%. All patients with positive nodes but one, and 72/161 (44.7%) with negative nodes and unfavourable prognostic factors underwent adjuvant radiation therapy. Results: The actuarial 5-year disease-free survival rate was 59.2% for the node-positive patients and 87.5% for the node-negative ones. Recurrence rate was 12.4% (20/161) in node-negative patients and 33.4% (18/54) in node-positive ones. There were 19 pelvic and 19 distant relapses, but there was a different behaviour between node-negative (14 pelvic and 6 distant) and node-positive cases (5 pelvic and 13 distant). The actuarial 5-year survival for relapsing patients was 22% for those with pelvic recurrences and 4% for patients with distant metastases. Conclusions: Our present policy in node-positive patients, given the higher incidence of distant metastases, is the use of chemotherapy as adjuvant treatment. In all node-negative subjects, but in positive parametria and positive margin cases, no adjuvant therapy is employed after radical surgery. Further studies should be designed to confirm this approach.

Original languageEnglish
Pages (from-to)93-100
Number of pages8
JournalItalian Journal of Gynaecology and Obstetrics
Volume11
Issue number3
Publication statusPublished - 1999

Fingerprint

Hysterectomy
Uterine Cervical Neoplasms
Therapeutics
Recurrence
Survival
Radiotherapy
Neoplasm Metastasis
Peritoneum
Incidence
Adjuvant Chemotherapy
Disease-Free Survival
Survival Rate
Carcinoma

Keywords

  • Adjuvant treatment
  • Cervical cancer
  • Early stages
  • Radical hysterectomy
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Evolving strategies in adjuvant treatment for stage IB cervical cancer after radical hysterectomy. / Sartori, E.; Zanagnolo, V.; Tisi, G.; Pecorelli, S.; Bianchi, U. A.

In: Italian Journal of Gynaecology and Obstetrics, Vol. 11, No. 3, 1999, p. 93-100.

Research output: Contribution to journalArticle

@article{2928bb8fd4844901a13d428641055b00,
title = "Evolving strategies in adjuvant treatment for stage IB cervical cancer after radical hysterectomy",
abstract = "Objective: In stage IB cervical cancer patients after radical hysterectomy adjuvant radiation therapy is usually performed in node-positive subjects or patients with unfavourable prognostic factors on the surgical specimen. The aim of this paper is to retrospectively analyze the patterns of failure and survival in patients with stage IB cervical cancer after radical hysterectomy in relation to the main prognostic factors in view of the evolving strategies in adjuvant treatment. Methods: Site of recurrence and survival data were reviewed for 215 stage IB cervical carcinoma patients after radical surgery in a 10-year period. The incidence of positive nodes was 25.2{\%}. All patients with positive nodes but one, and 72/161 (44.7{\%}) with negative nodes and unfavourable prognostic factors underwent adjuvant radiation therapy. Results: The actuarial 5-year disease-free survival rate was 59.2{\%} for the node-positive patients and 87.5{\%} for the node-negative ones. Recurrence rate was 12.4{\%} (20/161) in node-negative patients and 33.4{\%} (18/54) in node-positive ones. There were 19 pelvic and 19 distant relapses, but there was a different behaviour between node-negative (14 pelvic and 6 distant) and node-positive cases (5 pelvic and 13 distant). The actuarial 5-year survival for relapsing patients was 22{\%} for those with pelvic recurrences and 4{\%} for patients with distant metastases. Conclusions: Our present policy in node-positive patients, given the higher incidence of distant metastases, is the use of chemotherapy as adjuvant treatment. In all node-negative subjects, but in positive parametria and positive margin cases, no adjuvant therapy is employed after radical surgery. Further studies should be designed to confirm this approach.",
keywords = "Adjuvant treatment, Cervical cancer, Early stages, Radical hysterectomy, Recurrence, Survival",
author = "E. Sartori and V. Zanagnolo and G. Tisi and S. Pecorelli and Bianchi, {U. A.}",
year = "1999",
language = "English",
volume = "11",
pages = "93--100",
journal = "Italian Journal of Gynaecology and Obstetrics",
issn = "1121-8339",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "3",

}

TY - JOUR

T1 - Evolving strategies in adjuvant treatment for stage IB cervical cancer after radical hysterectomy

AU - Sartori, E.

AU - Zanagnolo, V.

AU - Tisi, G.

AU - Pecorelli, S.

AU - Bianchi, U. A.

PY - 1999

Y1 - 1999

N2 - Objective: In stage IB cervical cancer patients after radical hysterectomy adjuvant radiation therapy is usually performed in node-positive subjects or patients with unfavourable prognostic factors on the surgical specimen. The aim of this paper is to retrospectively analyze the patterns of failure and survival in patients with stage IB cervical cancer after radical hysterectomy in relation to the main prognostic factors in view of the evolving strategies in adjuvant treatment. Methods: Site of recurrence and survival data were reviewed for 215 stage IB cervical carcinoma patients after radical surgery in a 10-year period. The incidence of positive nodes was 25.2%. All patients with positive nodes but one, and 72/161 (44.7%) with negative nodes and unfavourable prognostic factors underwent adjuvant radiation therapy. Results: The actuarial 5-year disease-free survival rate was 59.2% for the node-positive patients and 87.5% for the node-negative ones. Recurrence rate was 12.4% (20/161) in node-negative patients and 33.4% (18/54) in node-positive ones. There were 19 pelvic and 19 distant relapses, but there was a different behaviour between node-negative (14 pelvic and 6 distant) and node-positive cases (5 pelvic and 13 distant). The actuarial 5-year survival for relapsing patients was 22% for those with pelvic recurrences and 4% for patients with distant metastases. Conclusions: Our present policy in node-positive patients, given the higher incidence of distant metastases, is the use of chemotherapy as adjuvant treatment. In all node-negative subjects, but in positive parametria and positive margin cases, no adjuvant therapy is employed after radical surgery. Further studies should be designed to confirm this approach.

AB - Objective: In stage IB cervical cancer patients after radical hysterectomy adjuvant radiation therapy is usually performed in node-positive subjects or patients with unfavourable prognostic factors on the surgical specimen. The aim of this paper is to retrospectively analyze the patterns of failure and survival in patients with stage IB cervical cancer after radical hysterectomy in relation to the main prognostic factors in view of the evolving strategies in adjuvant treatment. Methods: Site of recurrence and survival data were reviewed for 215 stage IB cervical carcinoma patients after radical surgery in a 10-year period. The incidence of positive nodes was 25.2%. All patients with positive nodes but one, and 72/161 (44.7%) with negative nodes and unfavourable prognostic factors underwent adjuvant radiation therapy. Results: The actuarial 5-year disease-free survival rate was 59.2% for the node-positive patients and 87.5% for the node-negative ones. Recurrence rate was 12.4% (20/161) in node-negative patients and 33.4% (18/54) in node-positive ones. There were 19 pelvic and 19 distant relapses, but there was a different behaviour between node-negative (14 pelvic and 6 distant) and node-positive cases (5 pelvic and 13 distant). The actuarial 5-year survival for relapsing patients was 22% for those with pelvic recurrences and 4% for patients with distant metastases. Conclusions: Our present policy in node-positive patients, given the higher incidence of distant metastases, is the use of chemotherapy as adjuvant treatment. In all node-negative subjects, but in positive parametria and positive margin cases, no adjuvant therapy is employed after radical surgery. Further studies should be designed to confirm this approach.

KW - Adjuvant treatment

KW - Cervical cancer

KW - Early stages

KW - Radical hysterectomy

KW - Recurrence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0032877871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032877871&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 93

EP - 100

JO - Italian Journal of Gynaecology and Obstetrics

JF - Italian Journal of Gynaecology and Obstetrics

SN - 1121-8339

IS - 3

ER -